









Markets
/
Stocks
/
nasdaq-mdwd
/

Mediwound Ltd

MDWD

18.030USD

-0.120-0.66%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

196.09MMarket Cap

LossP/E TTM



Mediwound Ltd

18.030

-0.120-0.66%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Mediwound Ltd

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Mediwound Ltd's Score

Industry at a Glance

Industry Ranking

96 / 159

Overall Ranking

255 / 4615

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

30.667

Target Price

+68.96%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Mediwound Ltd Highlights

StrengthsRisks

Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.

Growing

The company is in a growing phase, with the latest annual income totaling USD 20.22M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 20.22M.

Fairly Valued

The company’s latest PE is -6.93, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 5.86M shares, increasing 8.22% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 2.75K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.19.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 6.09, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 5.71M, representing a year-over-year increase of 12.74%, while its net profit experienced a year-over-year increase of 111.23%.

Score

Industry at a Glance

Previous score

6.09

Change



Financials

6.99

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.72

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

3.32

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.31

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Mediwound Ltd's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 6.31, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -6.93, which is -63.23% below the recent high of -2.55 and -231.23% above the recent low of -22.96.

Score

Industry at a Glance

Previous score

6.31

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 96/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 8.33, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Mediwound Ltd is 30.50, with a high of 39.00 and a low of 25.00.

Score

Industry at a Glance

Previous score

8.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Buy

Current Rating

30.667

Target Price

+68.96%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Mediwound Ltd

MDWD

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 6.66, which is lower than the Pharmaceuticals industry's average of 6.90. Sideways: Currently, the stock price is trading between the resistance level at 19.54 and the support level at 17.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.81

Change

-0.15

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.196

Neutral

RSI(14)

47.336

Neutral

STOCH(KDJ)(9,3,3)

40.286

Neutral

ATR(14)

0.676

Low Volatility

CCI(14)

-96.504

Neutral

Williams %R

79.051

Sell

TRIX(12,20)

0.074

Sell

StochRSI(14)

34.982

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

18.146

Sell

MA10

18.246

Sell

MA20

18.530

Sell

MA50

17.836

Buy

MA100

18.478

Sell

MA200

18.412

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 45.68%, representing a quarter-over-quarter decrease of 26.28%. The largest institutional shareholder is PRFDX, holding a total of 369.08K shares, representing 2.88% of shares outstanding, with 53207.41% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Clal Biotechnology Industries Ltd

1.48M

Investor AB

872.09K

Yelin Lapidot Provident Funds Management Ltd

816.74K

-4.81%

HOLD Alapkezelo Zrt

703.43K

Rosalind Advisors, Inc.

407.06K

-19.69%

BlackRock Institutional Trust Company, N.A.

388.27K

-10.54%

Israel Biotech Fund

378.62K

-31.32%

T. Rowe Price Associates, Inc.

Star Investors

369.08K

+138.19%

Deep Insight Limited Partnership

278.18K

-49.54%

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 4.84, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.07. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.